Literature DB >> 1388684

Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression.

J S Burns1, J P Blaydes, P A Wright, L Lemoine, J A Bond, E D Williams, D Wynford-Thomas.   

Abstract

Activating mutations of the ras oncogene family occur at high frequency in all stages of thyroid tumorigenesis, both human and experimental. To test the causal nature of this association, and to investigate the biological role of ras mutation, we introduced a mutant c-Ha-ras gene into normal rat thyroid follicular cells using an ecotropic retroviral vector. The major immediate effect was to greatly extend the proliferative lifespan of these cells in culture from less than 3 to more than 15 doublings, without any observable loss of growth-factor dependence or differentiated functions. This in vitro phenotype strongly supports an initiating role for ras mutation in the genesis of benign thyroid tumors (adenomas) in vivo. Spontaneous transformation was observed at low frequency on continuous culture of mutant ras-expressing cells, giving rise to fully immortalized, growth factor-independent, highly tumorigenic lines. Transformation was associated with (i) loss of responsiveness to the growth inhibitor TGF-beta 1, and (ii) greatly increased nuclear levels of p53 protein, which unexpectedly was not due to point mutation in the conserved regions of the p53-coding sequence. We postulate that these two phenomena are causally related to each other and to the transformed phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1388684     DOI: 10.1002/mc.2940060208

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

1.  Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.

Authors:  Yuri E Nikiforov; N Paul Ohori; Steven P Hodak; Sally E Carty; Shane O LeBeau; Robert L Ferris; Linwah Yip; Raja R Seethala; Mitchell E Tublin; Michael T Stang; Christopher Coyne; Jonas T Johnson; Andrew F Stewart; Marina N Nikiforova
Journal:  J Clin Endocrinol Metab       Date:  2011-08-31       Impact factor: 5.958

2.  H-ras-transformed NRK-52E renal epithelial cells have altered growth, morphology, and cytoskeletal structure that correlates with renal cell carcinoma in vivo.

Authors:  C J Best; L R Tanzer; P C Phelps; R L Merriman; G G Boder; B F Trump; K A Elliget
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-04       Impact factor: 2.416

3.  Role of epidermal growth factor receptor signaling in RAS-driven melanoma.

Authors:  Nabeel Bardeesy; Minjung Kim; Jin Xu; Ryung-Suk Kim; Qiong Shen; Marcus W Bosenberg; Wing H Wong; Lynda Chin
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

4.  RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers.

Authors:  Nikhil Gupta; Anil K Dasyam; Sally E Carty; Marina N Nikiforova; N Paul Ohori; Michaele Armstrong; Linwah Yip; Shane O LeBeau; Kelly L McCoy; Christopher Coyne; Michael T Stang; Jonas Johnson; Robert L Ferris; R Seethala; Yuri E Nikiforov; Steven P Hodak
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

Review 5.  Molecular approaches to thyroid cancer diagnosis.

Authors:  Susan J Hsiao; Yuri E Nikiforov
Journal:  Endocr Relat Cancer       Date:  2014-05-14       Impact factor: 5.678

6.  Differential effects of protein kinase A on Ras effector pathways.

Authors:  M J Miller; L Rioux; G V Prendergast; S Cannon; M A White; J L Meinkoth
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

7.  Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer.

Authors:  Koji Ando; Eiji Oki; Hiroshi Saeki; Zhao Yan; Yasuo Tsuda; Gen Hidaka; Yuta Kasagi; Hajime Otsu; Hiroyuki Kawano; Hiroyuki Kitao; Masaru Morita; Yoshihiko Maehara
Journal:  Cancer Med       Date:  2014-10-30       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.